Exact Mass: 455.0917782000001
Exact Mass Matches: 455.0917782000001
Found 103 metabolites which its exact mass value is equals to given mass value 455.0917782000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Cefotaxime
Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis). J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
(2R)-2-Hydroxy-2-(4-hydroxyphenyl)ethyl glucosinolate
(2S)-2-Hydroxy-2-(4-hydroxyphenyl)ethyl glucosinolate is found in brassicas. (2S)-2-Hydroxy-2-(4-hydroxyphenyl)ethyl glucosinolate is a constituent of Barbarea vulgaris ssp. arcuata and Barbarea orthoceras. Constituent of Barbarea vulgaris sspecies arcuata. (2R)-2-Hydroxy-2-(4-hydroxyphenyl)ethyl glucosinolate is found in brassicas.
Apafant
C22H22ClN5O2S (455.11826620000005)
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents
Cefotaxime, 98\%
Clevidipine
C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
5-O-(Butanoyloxymethyl) 3-O-methyl (4R)-4-(2,3-dichlorophenyl)-2,6-dimethyl-3,4-dihydropyridine-3,5-dicarboxylate
Clevidipine
C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
cefotaxime
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DD - Third-generation cephalosporins A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
AVE2865
C20H17ClF3N3O4 (455.08596280000006)
CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5073; ORIGINAL_PRECURSOR_SCAN_NO 5069 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5075; ORIGINAL_PRECURSOR_SCAN_NO 5074 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5043; ORIGINAL_PRECURSOR_SCAN_NO 5042 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5080; ORIGINAL_PRECURSOR_SCAN_NO 5079 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5074; ORIGINAL_PRECURSOR_SCAN_NO 5070 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5077; ORIGINAL_PRECURSOR_SCAN_NO 5075 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9536; ORIGINAL_PRECURSOR_SCAN_NO 9531 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9578; ORIGINAL_PRECURSOR_SCAN_NO 9573 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9586; ORIGINAL_PRECURSOR_SCAN_NO 9581 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9628; ORIGINAL_PRECURSOR_SCAN_NO 9624 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9633; ORIGINAL_PRECURSOR_SCAN_NO 9631 CONFIDENCE standard compound; INTERNAL_ID 632; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9647; ORIGINAL_PRECURSOR_SCAN_NO 9645
Cys Cys Cys Lys
C15H29N5O5S3 (455.13307440000005)
Cys Cys Cys Gln
Cys Cys Lys Cys
C15H29N5O5S3 (455.13307440000005)
Cys Cys Gln Cys
Cys Lys Cys Cys
C15H29N5O5S3 (455.13307440000005)
Cys Gln Cys Cys
Lys Cys Cys Cys
C15H29N5O5S3 (455.13307440000005)
Gln Cys Cys Cys
(2R)-2-Hydroxy-2-(4-hydroxyphenyl)ethyl glucosinolate
XL388
C23H22FN3O4S (455.13149840000005)
XL388 is a highly potent and ATP-competitive mTOR inhibitor with an IC50 of 9.9 nM. XL388 simultaneously inhibits both mTORC1 and mTORC2. XL388 is a highly potent and ATP-competitive mTOR inhibitor with an IC50 of 9.9 nM. XL388 simultaneously inhibits both mTORC1 and mTORC2.
2 5-BIS(CHLOROMETHYL)-1 4-BIS(BUTOXY)BE&
C26H21N3O3S (455.13035560000003)
fmoc-(r)-3-amino-3-(3-trifluoromethyl-phenyl)-propionic acid
C25H20F3NO4 (455.1344356000001)
(2S)-3-amino-2-(9H-fluoren-9-ylmethoxycarbonyl)-4-(2,4,5-trifluorophenyl)butanoic acid
C25H20F3NO4 (455.1344356000001)
fmoc-(s)-3-amino-3-(2,4-dichloro-phenyl)-propionic acid
C24H19Cl2NO4 (455.06910740000006)
fmoc-(s)-3-amino-3-(3-trifluoromethyl-phenyl)-propionic acid
C25H20F3NO4 (455.1344356000001)
fmoc-(s)-3-amino-3-(4-trifluoromethyl-phenyl)-propionic acid
C25H20F3NO4 (455.1344356000001)
(R)-3-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)AMINO)-4-(2,4,5-TRIFLUOROPHENYL)BUTANOIC ACID
C25H20F3NO4 (455.1344356000001)
Fmoc-(S)-3-Amino-3-(2,3-dichlorophenyl)-propionic acid
C24H19Cl2NO4 (455.06910740000006)
fmoc-(r)-3-amino-3-(4-trifluoromethyl-phenyl)-propionic acid
C25H20F3NO4 (455.1344356000001)
Methyl (E)-2-[3-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-oxopropyl]benzoate
C28H22ClNO3 (455.1288132000001)
fmoc-(r)-3-amino-3-(2-trifluoromethyl-phenyl)-propionic acid
C25H20F3NO4 (455.1344356000001)
GADOLINIUM(III) ACETYLACETONATE HYDRATE&
C15H21GdO6 (455.05791760000005)
primaquine phosphate
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
fmoc-3,4-dichloro-l-phenylalanine
C24H19Cl2NO4 (455.06910740000006)
3-(3,4-dichloro-phenyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-propionic acid
C24H19Cl2NO4 (455.06910740000006)
Methyl 2-(3-{3-[2-(7-chloroquinolin-2-yl)vinyl]phenyl}-3-oxopropyl)benzoate
C28H22ClNO3 (455.1288132000001)
[(5-chloro-3-oxidobenzotriazol-3-ium-1-yl)-morpholin-4-ylmethylidene]-dimethylazanium,hexafluorophosphate
C13H17ClF6N5O2P (455.07125340000005)
fmoc-(r)-3-amino-3-(2,4-dichloro-phenyl)-propionic acid
C24H19Cl2NO4 (455.06910740000006)
4,8-bis(thiophen-2-yl)-6-(2-ethylhexyl)-[1,2,5]thiadiazolo[3,4-f]benzotriazole
fmoc-(s)-3-amino-3-(2-trifluoromethyl-phenyl)-propionic acid
C25H20F3NO4 (455.1344356000001)
Abt-639
C20H20ClF2N3O3S (455.08819040000003)
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent C93038 - Cation Channel Blocker
N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4a,5,6,8-tetrahydro-4H-pyrano(3,4-d)(1,3)thiazin-8a-yl)thiazol-4-yl)-5-(difluoromethoxy)pyridine-2-carboxamide
C18H19F2N5O3S2 (455.08973280000004)
1-(2-((((2-Chloro-4,5-difluorophenyl)carbonyl)carbamoyl)amino)-4-fluorophenyl)piperidine-4-carboxylic acid
C20H17ClF3N3O4 (455.08596280000006)
Claforan
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
1-[(4-Chlorophenyl)methyl]-4-(4-chlorophenyl)sulfonyl-4-piperidinecarboxylic acid ethyl ester
C21H23Cl2NO4S (455.07247780000006)
N-(5-chloro-2-methoxyphenyl)-2-[[3-(2-methoxyethyl)-6-methyl-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl]sulfanyl]acetamide
C19H22ClN3O4S2 (455.07402020000006)
[2-[2-Morpholin-4-yl-5-(trifluoromethyl)anilino]-2-oxoethyl] 2-methylsulfanylpyridine-3-carboxylate
C20H20F3N3O4S (455.1126556000001)
N-(3,5-dimethylphenyl)-2-[(4-oxo-3-phenyl-2-benzofuro[3,2-d]pyrimidinyl)thio]acetamide
C26H21N3O3S (455.13035560000003)
{4-[2,2-Bis(5-methyl-1,2,4-oxadiazol-3-YL)-3-phenylpropyl]phenyl}sulfamic acid
C21H21N5O5S (455.12633360000007)
N-(3-Chlorophenyl)-N-Methyl-2-Oxo-3-[(3,4,5-Trimethyl-1h-Pyrrol-2-Yl)methyl]-2h-Indole-5-Sulfonamide
C23H22ClN3O3S (455.10703320000005)
Apafant
C22H22ClN5O2S (455.11826620000005)
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents D050299 - Fibrin Modulating Agents D002317 - Cardiovascular Agents
(E)-1-(glutathion-S-yl)-N-hydroxy-2-(4-hydroxyphenyl)ethan-1-imine
10-[3-[4-(2-Chloroethyl)-1-piperazinyl]propyl]-2-(trifluoromethyl)phenothiazine
C22H25ClF3N3S (455.14097160000006)
3-(2-chlorophenyl)-5-methyl-N-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-4-isoxazolecarboxamide
C23H22ClN3O5 (455.12479120000006)
4-tert-butyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]benzenesulfonamide
[2-methoxy-5-[(E)-[(3-nitrobenzoyl)hydrazinylidene]methyl]phenyl] benzenesulfonate
5-[[4-(2,6-Difluorophenyl)sulfonyl-1-piperazinyl]sulfonyl]-1-methylindole
C19H19F2N3O4S2 (455.07849980000003)
1-[4-(4-bromophenyl)-2-thiazolyl]-N-(phenylmethyl)-4-piperidinecarboxamide
C22H22BrN3OS (455.06668620000005)
N,N-diethyl-3-[(4-fluorophenyl)sulfonylamino]-4-(1-pyrrolidinyl)benzenesulfonamide
C20H26FN3O4S2 (455.13486880000005)
2-[[[3-[2-(4-Methylphenyl)sulfonylethylthio]phenyl]-oxomethyl]amino]benzoic acid
C23H21NO5S2 (455.08610960000004)
3,4-dimethoxy-N-[4-(2,2,3,3-tetrafluoropropoxy)-3-(trifluoromethyl)phenyl]benzamide
C19H16F7NO4 (455.09675000000004)
N-(2-methoxyphenyl)-5-methyl-3-(1-naphthalenylmethyl)-4-oxo-6-thieno[2,3-d]pyrimidinecarboxamide
C26H21N3O3S (455.13035560000003)
2-[[benzyl-[(2-fluorophenyl)methyl]carbamothioyl]amino]-N-[(4-chlorophenyl)methyl]acetamide
C24H23ClFN3OS (455.12343100000004)
2-[[4-(3,4-dimethylphenyl)-1-phenyl-2-imidazolyl]thio]-N-(1,1-dioxo-3-thiolanyl)acetamide
C23H25N3O3S2 (455.13372599999997)
[(2R,3S,4S)-5-(7,8-dimethyl-2-oxido-4-oxo-3,5-dihydrobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] phosphate
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1-hydroxy-3-oxo-1-phenylpropan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(2-hydroxyphenyl)-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
(2S)-2-[[2-(3-hydroxy-5-oxo-4-phenylfuran-2-ylidene)-2-phenylacetyl]amino]-3-phenylpropanoic acid
C27H21NO6 (455.13688060000004)
4,7-DI(4-Methoxyphenyl)-6-(2-methoxyphenyl)-1,2,5-thiadiazolo(3,4-C)pyridine
C26H21N3O3S (455.13035560000003)
FMNH2(3-)
A organophosphate oxoanion obtained by deprotonation of the phosphate OH groups as well as position N1 of FMNH2.
Bromperidol (hydrochloride)
Bromperidol (R-11333) hydrochloride possesses antipsychotic activity, with a high affinity for central dopamine receptors D2. Bromperidol hydrochloride can kill Mycobacteria in a synergistic manner with Spectinomycin[1][2].
2,6-dichloro-1-[5,6-dihydroxy-3-(hydroxymethyl)-4-methoxycyclohex-2-en-1-yl]-5-hydroxy-8-methylchromeno[2,3-b]pyrrol-4-one
C20H19Cl2NO7 (455.05385240000004)